New Delhi, Dec 20 (PTI) Bain Capital-backed Emcure Pharmaceuticals has filed fresh preliminary papers with capital markets regulator Sebi to raise funds through an Initial Public Offering (IPO).

The IPO comprises a fresh issuance of equity shares worth Rs 800 crore and an Offer of Sale (OFS) of 1.36 crore equity shares by promoters and existing shareholders, according to the fresh draft red herring prospectus filed last week.

Also Read | SBI Clerk Prelims Exam 2023: Admit Card for Preliminary Examination of Junior Associates Likely To Be Released Soon at sbi.co.in, Know How To Download.

Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.

Currently, Satish Mehta holds a 41.92 per cent stake in the company and BC Investments owns a 13.09 per cent stake.

Also Read | DU Recruitment 2023: Vacancies Notified for 51 Assistant Professor Posts, Apply Online at colrec.uod.ac.in.

Proceeds of the fresh issue will be used towards payment of debt and for general corporate purposes.

Earlier, the company had filed draft IPO papers with the Securities and Exchange of India (Sebi) in August 2021. The issue comprised a fresh issue of Rs 1,100 crore, and an OFS of 1.8 crore equity shares.

Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the book-running lead managers to the issue.

The equity shares are proposed to be listed on BSE and NSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)